Press Releases

Biotechnology innovations and commercialization of renewable chemicals will be featured topics of plenary sessions at the 2013 Pacific Rim Summit on Industrial Biotechnology and Bioenergy. This is the original conference dedicated to partnering and growth of the industrial biotechnology and bioenergy sectors in North America and the Asia-Pacific region. BIOCOM is the co-organizer to this year's event, which will be held in San Diego, California from December 8 -11, 2013 at the Westin Gaslamp Quarter.

 

BIO’s former legislator of the year to speak November 12 in Beijing 

Despite overwhelming bipartisan approval, California Governor Jerry Brown vetoed legislation designed to address the regulatory issues related to the interchangeability of biological medicines.
 

The Biotechnology Industry Organization’s (BIO) 2013 Pacific Rim Summit on Industrial Biotechnology and Bioenergy will feature presentations on recent innovations in using synthetic biology for renewable chemicals and algae biofuels.

The Biotechnology Industry Organization (BIO) invites leaders from the biotechnology, chemical and agricultural industries to submit proposals and individual papers for the 2014 World Congress on Industrial Biotechnology.

Sessions to focus on the IPO market, early stage venture financing, and BioCentury’s Back to School issue

NSF-funded companies focused on drug discovery, diagnostics and other platform technologies.

BIO and 38 member companies and organization today wrote a letter of thanks to Reps. Bill Pascrell (D-N.J.), Steve Stockman (R-Texas), and others who sponsored the Qualifying Renewable Chemical Production Tax Credit of 2013.

BIO, member companies, and state affiliates delivered letters to House and Senate Agriculture Committee members, urging finalization of a five-year Farm Bill with robust mandatory funding of the Energy Title and eligibility for renewable chemicals.

BIO asks EPA Administrator to reject a petition from petroleum industry trade groups to waive the 2014 RFS obligations. The harm that the trade groups predict can be avoided with sufficient time to plan compliance strategies.

The Biotechnology Industry Organization (BIO) today announced breakout sessions for the 2013 Pacific Rim Summit on Industrial Biotechnology and Bioenergy.  Summit will highlight progress in commercializing biofuels, renewable chemicals. The eighth annual Pacific Rim Summit will be co-organized by BIOCOM and held in San Diego, December 8-11 at the Westin Gaslamp Quarter.

The global event for biotech to take place in San Diego, CA June 23-26, 2014

Today, September 12, 2012, The Biotechnology Industry Organization (BIO) thanked Rep. Bill Pascrell (D-N.J.), Rep. Steve Stockman (R-Texas) and other original co-sponsors for introducing the Qualifying Renewable Chemical Production Tax Credit Act of 2013, which provides renewable chemical producers access to production tax credits currently available for other renewable energy producers. 

Speakers will provide fresh insight, investment opportunities in biotech sector.

Pending Legislation will Protect Pennsylvanians Utilizing Biologic Medications to Manage Chronic Diseases and other Unmet Medical Needs

Jim Greenwood, President and CEO of BIO, issued the following statement on the California Senate's passage of Senate Bill 598.

BIO President & CEO Jim Greenwood spoke at the ribbon cutting ceremony of Gevo's new demonstration-scale biorefinery in Silsbee, Texas, which will process 100,000 lbs. of renewable chemicals per year.

BIO applauds Rep. Michael Burgess (R-TX) and Rep. Jackie Speier (D-CA) for introducing the Medical Testing Availability Act of 2013 (H.R. 3005). 

The BIO Investor Forum will be from October 8-9, 2013 in San Francisco, California.

BIO urges EPA to continue to resist the oil refining industry's efforts to set up market barriers through this regulatory system.

S. 1413 and H.R. 2725 would exempt future FDA user fees from sequestration.

BIO Jobs is your online resource for biotechnology employment opportunities.

BIO released a statement in support of the FDA Safety Over Sequestration Act (H.R. 2725), which would exempt user fees, including those paid by BIO member companies, from the operation of sequestration.